ABEO Abeona Therapeutics Inc.

5.05
+0  (0%)
Previous Close 5.05
Open 5.05
Price To book 2.68
Market Cap 201.79M
Shares 39,959,000
Volume 190,008
Short Ratio 10.84
Av. Daily Volume 271,652

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment commenced September 2016.
ABO-101
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 updated data released February 17, 2017.
ABO-102
Sanfilippo syndrome type A (MPS IIIA)

Latest News

  1. Abeona Therapeutics to Present at Multiple Upcoming Investor Conferences
  2. Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa
  3. Abeona Therapeutics To Present At The Cowen and Company 37th Annual Health Care Conference
  4. Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
  5. In Honor of International Rare Disease Day, Abeona Therapeutics (Nasdaq: ABEO) Set to Ring the Nasdaq Stock Market Closing Bell
  6. ABEONA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  7. Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
  8. Abeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress
  9. ABEONA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  10. Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017
  11. 3 Companies Looking to Capitalize on Orphan Designation with Multiple Catalyst
  12. Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%
  13. IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  14. ABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Abeona Therapeutics Inc. and a Lead Plaintiff Deadline of February 14, 2017
  15. INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  16. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO) and Lead Plaintiff Deadline - February 14, 2017
  17. IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm
  18. EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Abeona Therapeutics Inc. - ABEO
  19. Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium(TM) 2017
  20. Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017